FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W39958532> ?p ?o ?g. }

• W39958532 abstract "Abstract Background Based on data from the CDC, over the next 20 years, approximately 12,500 patients (pt) with bleeding disorders will require a screening colonoscopy. For a 75 kg adult receiving an average factor dose of 35 units/kg, this translates into utilization of approximately 30 million units over this time period which will vary with pt weight and disease severity. In the absence of evidence based guidelines, current practice is to provide prophylactic clotting factor concentrates to all such pt. Herein we report our institutional experience. Materials and Methods Retrospective chart review of Mayo Comprehensive Hemophilia Treatment Center pt undergoing colonoscopies. Eligible pt had congenital von Willebrand disease (VWD), hemophilia A (HA) and B (HB). Data collected included pt demographics, factor concentrate and antifibrinolytic agent use, biopsy and polypectomy procedures, and bleeding complications (up to 1 month). Results From 1993-2013, 69 pt underwent 130 colonoscopies, 40/69 (58%) were males. Median (range) age at the time of the procedure was 60 years (3 to 87). The distribution of diagnoses were as follows: HA mild n=13, moderate n=5, severe n=5 and severe with inhibitor n=1; symptomatic carrier of HA n=2; HB mild n=6, severe n=1; VWD types 1: n=23, 2A: n=5, 2B: n=5, 2M: n=2; 3: n=3. 40/69 (58%) pt had one colonoscopy, the remainder 2 to 8 colonoscopies. The procedures were performed as outpatient in 119 (92%) and as inpatient in 11 (8%). Colonoscopy indications included: GI bleeding (49/130, 38%); screening (32/130, 25%); history of polyps (24/130, 18%); iron deficiency anemia (7/130, 6%); Crohn’s disease (5/130, 4%); diarrhea (4/130, 3%); colon cancer followup (3/130, 2%); abnormal imaging (3/130, 2%); family history of colon cancer, diverticulitis, and ulcerative colitis (combined 3/130, 2%). Of the 130 procedures, 25/130 (19%) received no factor or antifibrinolytic treatment, 58/130 (45%) received pre-procedure prophylactic factor only, 1/130 (1%) received post-procedure factor only, 29/130 (22%) received both, 3/130 (2%) received pre-factor and an antifibrinolytic, 3/130 (2%) received post-factor and an antifibrinolytic, 11/130 (8%) received pre and post-procedure factor and an antifibrinolytic. None received an antifibrinolytic alone. Biopsy was performed in only 56/130 (43%) of colonoscopies. Types of biopsies: polyp 37/56 (66%), mucosal 11/56 (20%), mucosal & polyp 5/56 (9%), lesion 1/56 (2%), lesion & polyp 2/56 (4%). Of the pt receiving a biopsy, 39/56 (70%) received pre-procedure factor and 25/56 (45%) received post-procedure factor. The pt most likely to be biopsied were those with an indication of history of polyps 15/56 (27%), GI bleed 13/56 (23%), screening 10/56 (18%), and Crohn’s disease/colon cancer follow up/ diarrhea/iron deficiency anemia each 3/56 (5%). Of the total number of procedures, 39/130 (30%) underwent a polypectomy. Of these, 26/39 (67%) received pre-procedure factor and 17/39 (44%) received post-procedure factor. The average number of polypectomies per patient was 2.3 and the average number of polyps removed per procedure was 3.2. Hemorrhagic complications were noted in 26/130 procedures (13/26 procedural only, 4/26 post-procedure only, 9/26 both), of which 8/26 (31%) were major (requiring hospitalization or RBC transfusion) and 18/26 (69%) were minor (requiring factor or observation). Of all the bleeding complications observed, 15/26 (58%) received factor alone (3/15 major bleeds, 12/15 minor bleeds), 3/26 (11%) received nothing (3/3 minor bleeds), and 8/26 (31%) received a combination of factor concentrate and an antifibrinolytic (5/8 major bleeds, 3/8 minor bleeds). There were 14/56 (25%) pt who underwent a biopsy or polypectomy without receiving any pre/post factor or antifibrinolytic. In 3/14 (21%), there was a minor bleeding complication and in 0/14 (0%), there was a major bleeding complication. No pt experienced colonic perforation. Conclusion In this study, most pt did not receive a biopsy or polypectomy. A risk stratification approach could be taken when deciding on factor concentrate infusions. For low risk pt, factor could be withheld but with post-procedure infusion provided for those undergoing biopsy or polypectomy. For high risk pt, current practices are reasonable. Based on the results presented here and the potential magnitude of impact, this topic deserves further study in a prospective fashion. Disclosures: No relevant conflicts of interest to declare." @default.
• W39958532 created "2016-06-24" @default.
• W39958532 creator A5013828509 @default.
• W39958532 creator A5016151411 @default.
• W39958532 date "2013-11-15" @default.
• W39958532 modified "2023-09-28" @default.
• W39958532 title "Outcomes Of Colonoscopies In Patients With Bleeding Disorders" @default.
• W39958532 doi "https://doi.org/10.1182/blood.v122.21.1115.1115" @default.
• W39958532 hasPublicationYear "2013" @default.
• W39958532 type Work @default.
• W39958532 sameAs 39958532 @default.
• W39958532 citedByCount "0" @default.
• W39958532 crossrefType "journal-article" @default.
• W39958532 hasAuthorship W39958532A5013828509 @default.
• W39958532 hasAuthorship W39958532A5016151411 @default.
• W39958532 hasConcept C121608353 @default.
• W39958532 hasConcept C126322002 @default.
• W39958532 hasConcept C141071460 @default.
• W39958532 hasConcept C167135981 @default.
• W39958532 hasConcept C187212893 @default.
• W39958532 hasConcept C2778435480 @default.
• W39958532 hasConcept C2778780528 @default.
• W39958532 hasConcept C2779394231 @default.
• W39958532 hasConcept C2780581329 @default.
• W39958532 hasConcept C2992139802 @default.
• W39958532 hasConcept C526805850 @default.
• W39958532 hasConcept C71924100 @default.
• W39958532 hasConcept C89560881 @default.
• W39958532 hasConcept C90924648 @default.
• W39958532 hasConceptScore W39958532C121608353 @default.
• W39958532 hasConceptScore W39958532C126322002 @default.
• W39958532 hasConceptScore W39958532C141071460 @default.
• W39958532 hasConceptScore W39958532C167135981 @default.
• W39958532 hasConceptScore W39958532C187212893 @default.
• W39958532 hasConceptScore W39958532C2778435480 @default.
• W39958532 hasConceptScore W39958532C2778780528 @default.
• W39958532 hasConceptScore W39958532C2779394231 @default.
• W39958532 hasConceptScore W39958532C2780581329 @default.
• W39958532 hasConceptScore W39958532C2992139802 @default.
• W39958532 hasConceptScore W39958532C526805850 @default.
• W39958532 hasConceptScore W39958532C71924100 @default.
• W39958532 hasConceptScore W39958532C89560881 @default.
• W39958532 hasConceptScore W39958532C90924648 @default.
• W39958532 hasLocation W399585321 @default.
• W39958532 hasOpenAccess W39958532 @default.
• W39958532 hasPrimaryLocation W399585321 @default.
• W39958532 hasRelatedWork W1671705540 @default.
• W39958532 hasRelatedWork W1967841624 @default.
• W39958532 hasRelatedWork W1979369596 @default.
• W39958532 hasRelatedWork W2040743742 @default.
• W39958532 hasRelatedWork W2053611738 @default.
• W39958532 hasRelatedWork W2077431179 @default.
• W39958532 hasRelatedWork W2164833456 @default.
• W39958532 hasRelatedWork W2349025374 @default.
• W39958532 hasRelatedWork W2382057779 @default.
• W39958532 hasRelatedWork W2410209047 @default.
• W39958532 hasRelatedWork W2796278917 @default.
• W39958532 hasRelatedWork W2801613241 @default.
• W39958532 hasRelatedWork W2919459470 @default.
• W39958532 hasRelatedWork W2922494970 @default.
• W39958532 hasRelatedWork W2947539029 @default.
• W39958532 hasRelatedWork W2985803462 @default.
• W39958532 hasRelatedWork W2995120877 @default.
• W39958532 hasRelatedWork W2998054933 @default.
• W39958532 hasRelatedWork W3088790085 @default.
• W39958532 hasRelatedWork W3107175151 @default.
• W39958532 isParatext "false" @default.
• W39958532 isRetracted "false" @default.
• W39958532 magId "39958532" @default.
• W39958532 workType "article" @default.